Clinical and biologic characteristics of MSLN−and MSLN+children and young adult patients treated on AAML1031
| Characteristic . | MSLN− (<5 TPM), n = 679 . | MSLN+ (≥5 TPM), n = 359 . | P . |
|---|---|---|---|
| Males | 344 (50.7) | 193 (53.8) | .342 |
| Age, median (range), y | 11.1 (0.04-29.5) | 8.3 (0-28.3) | .002 |
| CNS disease classification | |||
| CNS1 | 488 (73.3) | 206 (60.4) | <.001 |
| CNS2 | 126 (19.1) | 90 (26.4) | .008 |
| CNS3 | 50 (7.6) | 45 (13.2) | .004 |
| Non-CNS EMD present | 84 (12.4) | 61 (17) | .042 |
| Any EMD (non-CNS + CNS3) | 125 (18.8) | 95 (27.8) | .001 |
| Diagnostic WBC count, median (range), ×103/μL | 19.9 (0.6-918.5) | 28.1 (0.6-712.7) | .116 |
| Bone marrow blasts, median (range), % | 68 (0-100) | 70 (0-100) | .074 |
| Peripheral blasts, median (range), % | 36 (0-100) | 40 (0-99) | .791 |
| CEBPα positive | 62 (9.1) | 0 (0) | <.001 |
| NPM1 positive | 91 (13.4) | 5 (1.4) | <.001 |
| FLT3-ITD positive | 156 (23) | 12 (3.3) | <.001 |
| Cytogenetics | |||
| Normal | 257 (36.9) | 10 (2.8) | <.001 |
| inv(16)/t(16;16) | 12 (1.8) | 89 (24.9) | <.001 |
| t(8;21) | 57 (8.5) | 86 (24) | <.001 |
| 11q23/KMT2A rearrangements | 87 (13) | 144 (40.2) | <.001 |
| Monosomy 5/del5q | 10 (1.5) | 0 (0) | .018 |
| Monosomy 7 | 18 (2.7) | 1 (0.3) | .006 |
| Trisomy 8 | 50 (7.5) | 13 (3.6) | .015 |
| Other abnormalities | 159 (23.7) | 14 (3.9) | <.001 |
| Complete remission at end of induction I | 479 (72.1) | 269 (82.3) | <.001 |
| MRD < 0.1% at end of induction I | 406 (63.7) | 301 (87.8) | <.001 |
| Characteristic . | MSLN− (<5 TPM), n = 679 . | MSLN+ (≥5 TPM), n = 359 . | P . |
|---|---|---|---|
| Males | 344 (50.7) | 193 (53.8) | .342 |
| Age, median (range), y | 11.1 (0.04-29.5) | 8.3 (0-28.3) | .002 |
| CNS disease classification | |||
| CNS1 | 488 (73.3) | 206 (60.4) | <.001 |
| CNS2 | 126 (19.1) | 90 (26.4) | .008 |
| CNS3 | 50 (7.6) | 45 (13.2) | .004 |
| Non-CNS EMD present | 84 (12.4) | 61 (17) | .042 |
| Any EMD (non-CNS + CNS3) | 125 (18.8) | 95 (27.8) | .001 |
| Diagnostic WBC count, median (range), ×103/μL | 19.9 (0.6-918.5) | 28.1 (0.6-712.7) | .116 |
| Bone marrow blasts, median (range), % | 68 (0-100) | 70 (0-100) | .074 |
| Peripheral blasts, median (range), % | 36 (0-100) | 40 (0-99) | .791 |
| CEBPα positive | 62 (9.1) | 0 (0) | <.001 |
| NPM1 positive | 91 (13.4) | 5 (1.4) | <.001 |
| FLT3-ITD positive | 156 (23) | 12 (3.3) | <.001 |
| Cytogenetics | |||
| Normal | 257 (36.9) | 10 (2.8) | <.001 |
| inv(16)/t(16;16) | 12 (1.8) | 89 (24.9) | <.001 |
| t(8;21) | 57 (8.5) | 86 (24) | <.001 |
| 11q23/KMT2A rearrangements | 87 (13) | 144 (40.2) | <.001 |
| Monosomy 5/del5q | 10 (1.5) | 0 (0) | .018 |
| Monosomy 7 | 18 (2.7) | 1 (0.3) | .006 |
| Trisomy 8 | 50 (7.5) | 13 (3.6) | .015 |
| Other abnormalities | 159 (23.7) | 14 (3.9) | <.001 |
| Complete remission at end of induction I | 479 (72.1) | 269 (82.3) | <.001 |
| MRD < 0.1% at end of induction I | 406 (63.7) | 301 (87.8) | <.001 |
Unless otherwise noted, data are n (%).
CNS1, no blasts identified; CNS2, blasts present on cytospin with white blood cells (WBC) <5 or blasts present on cytospin with WBC ≥5 and traumatic tap; CNS3, blasts present on cytospin with WBC ≥5 and atraumatic tap.